T1	Participants 33 151	antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial
T2	Participants 575 709	136 antiretroviral-naïve patients, with a CD4 cell count above 100 cells/microL and a plasma HIV RNA below 100,000 HIV-1 RNA copies/mL
T3	Participants 864 935	patients in the lopinavir/ritonavir monotherapy arm followed to week 96
